Skip to main contentSkip to footer
A finger pointing at a scan
Brighton & Sussex Medical School

staff profiles

BSMS > About BSMS > Contact us > Staff > Professor Sumita Verma

Professor Sumita Verma

Prof Sumita Verma

Professor Sumita Verma (MBBS, MD, FRCP)

Professor and Honorary Consultant in Hepatology
T: +44 (0)1273 877890
Location: Medical Teaching Building, Rm 2.17, BSMS, University of Sussex, BN1 9PX

DA: Lisa Costick
T: +44 (0)1273 877890

Other roles: Assistant Professor Hepatology, University of Southern California (USC), Los Angeles, California, USA, March 2002-Aug 2004
Assistant Professor in Hepatology, Johns Hopkins University Hospital (JHUH), Baltimore, Maryland, USA, April 2006-Feb 2007

Areas of expertise: Cirrhosis and its complications; alcohol and hepatitis C-related liver disease; drug-induced liver injury; autoimmune hepatitis 

Research areas: Developing integrated community models of care to help achieve HCV elimination; imaging hepatic neutrophil migration as a non-invasive diagnostic tool in severe alcoholic hepatitis; novel interventions to improve symptom burden in refractory ascites due to advanced cirrhosis 


After obtaining her medical degree from the University of Delhi, Sumita came to the UK in 1992 and trained as a Gastroenterologist/ Hepatologist in Yorkshire (Hull, Leeds and York).  She subsequently worked as an Academic Hepatologist (Assistant Professor) at USC and JHUH.  Sumita was appointed as a Senior Lecturer BSMS, Hon consultant Hepatology BSUH in 2007. She is the academic Lead for Hepatology at BSUH and holds a Hon Consultant contract at the Institute of Liver Studies, Kings College Hospital (KCH) where she attends a post transplant liver clinic. In 2011 BSUH was recognised for level two training in Hepatology by Kent Surrey and Sussex Deanery and in 2014 designated a national hepatitis C centre by NHS England to deliver the new hepatitis C drugs. In addition, Sumita contributes to multiple BSMS activities including Phase 2 leader (2009), director of undergraduate student support (Jan 2014 –Sept 16), examining (CBD, OSCE) and interviewing BSMS students and supervising year 4 Individual Research Projects.


Sumita has developed Hepatology research at BSMS, receiving approximately one million pounds in grant funding. This includes funding from the National Institute of Health Research (NIHR) (250K), The Dunhill Medical Trust (DMT) (£134K) and Gilead Sciences (395K). She has forged successful collaborations nationally (BSMS/BSUH, Nottingham, KCH and Surrey University) and internationally (Johns Hopkins University Hospitals).

Nationally, death from liver disease has increased 500% over the last 40 years, delayed diagnosis being an important factor. Professor Verma’s research is in line with national strategy, focusing on

  1. Simple non-invasive tests (AST/ALT ratio, FIB4 test), scans (transient elastrography), and imaging (see below) for timely diagnosis, stratification and treatment of chronic liver disease both in the community and hospital setting. She has established community models of care at a substance misuse clinic (Project ITTREAT, funder Gilead Sciences) and GP practices catering to the homeless (VALID project, Funder DMT). These innovative models have the potential to be adopted nationally. 
  2. Imaging hepatic neutrophil migration (radionuclide/PET scanning) as a potential non-invasive diagnostic test for severe alcoholic hepatitis (funder BSMS) 
  3. Improving symptom burdened in advanced cirrhosis and refractory ascites with long-term abdominal drains (RCT, funder NIHR)

To date Sumita has supervised three PhD students, an Academic Clinical Fellow, multiple Academic F2, a Research Nurse and multiple year 4 individual research projects.


Sumita is QUESP (part 1 and 2) qualified and is a GMC recognised undergraduate trainer. She has developed and integrated Hepatology throughout the BSMS undergraduate curriculum: SCC on non-alcoholic stetaohepatitis (year 2); Introduction to Hepatology and pathogenesis of viral hepatitis lectures (module 302); 5 weeks of GI/Liver teaching CBD format (module 303) and Gastroenterology/Hepatology revision lectures for years 3 and 5. 

Sumita is the recipient of the BSMS Top Teacher in Year 3 award in 2009/10, 2013/14, 2014/15, and 2015/16 and top teacher in year 5 award 2017/2018. 

She also regularly contributes to foundation doctor (acute liver failure) and core medical (infectious hepatitis) teaching. 

Selected publications

Macken L, Mason L, Evans C, Gage H, Jordan J, Austin M, Parnell N, Cooper M, Steer S, Boles J, Bremner S,  Lambert D, Crook D, Earl G, Timeyn J, Verma S.  Palliative long-term abdominal drains versus repeated drainage in individuals with untreatable ascites due to advanced cirrhosis: study protocol for a feasibility randomised controlled trial. Trials. 2018;19:401                 

Potts JR, Howard MR, Taylor M, Farahi N, Heard S, Shankar A, Alexander GJ, Chilvers ERC, Verma S,* Peters AM*. In vivo imaging of hepatic neutrophil migration with radiolabelled leucocytes; a new diagnostic tool in severe alcoholic hepatitis. Bioscience Reports Citation. 2018;38(4).BSR20180466. * joint senior authors

Hashim A, O’Sullivan M, Williams H, Verma S. Developing a Community HCV Service: Project ITTREAT (Integrated Community based Test - stage - TREAT) Service for People who Inject Drugs. Primary Health Care Research and Development.  2018: 19(2):110-120 

Shur N, Fisher M, Goubet S, Gilleece Y, Verma S. Non-viral liver disease  burden in HIV positive individuals. A longitudinal retrospective cohort study. AIDS Care. 2016;28:1522-1527 

Potts JR, Goubet S, Heneghan MA, Verma S. Determinants of long-term outcome in severe alcoholic hepatitis. Alimentary Pharmacology and Therapeutics 2013;38:584-95

El Sherrif Y,  Potts JR,  Howard MR,  Barnardo A, Cairns S,  Knisely AS, Verma S. Hepatotoxicity From Anabolic Androgenic Steroids Marketed As Dietary Supplements: Contribution from ATP8B1 / ABCB11 Mutations? Liver International 2013;33:1226-70

Verma S, Kaplowitz N. Recent advances in clinical practice. Diagnosis management and prevention of drug induced liver injury. Gut 2009;58:1555-64• Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007:46:1828-1835

Verma S, Bonacini M, Govindarajan S, Kanel G, Lindsay KL, Redeker A.More advanced hepatic fibrosis in Hispanic patients with chronic hepatitis C:role of patient demographics, hepatic necroinflammation and steatosis. American Journal of Gastroenterology 2006;101:1817-1823 

Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Does  type and duration of antiretroviral therapy  attenuate liver fibrosis in HIV/HCV coinfected patients. Clinical Infectious Disease 2006;42:262-70. 

Verma S, Gunawan B, Mendler MH, Govindrajan S, Redeker A: Factors  predicting relapse and poor outcome in Type 1 autoimmune hepatitis: Role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. American Journal of Gastroenterology 2004;99:  1510-6